{
    "nct_id": "NCT04993677",
    "official_title": "An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies",
    "inclusion_criteria": "* Histologically or cytologically confirmed unresectable malignancy defined as one of the following:\n\n  * Cohort 1: Relapsed and/or refractory metastatic melanoma\n\n    * Uveal/ocular melanoma is excluded\n    * Must have progressed on treatment with an anti-PD-(L)1 mAb. PD-(L)1 treatment progression is defined as meeting all of the following criteria:\n\n      * Has received at least 2 doses of an approved anti-PD-(L)1 mAb\n      * Has demonstrated disease progression after PD-(L)1 as defined by RECIST v1.1.\n      * Progressive disease has been documented within 12 weeks from the last dose of anti- PD-(L)1 mAb\n      * Last dose of anti-PD-(L)1 must have been within 90 days prior to enrollment\n    * Participants with a targetable BRAF mutation must have been treated with, been intolerant of, or declined treatment with BRAF/MEK targeted therapy prior to study entry\n  * Cohort 2: Metastatic uveal melanoma\n\n    * Must not have received prior treatment for advanced or metastatic disease except for prior adjuvant/neoadjuvant immunotherapy\n    * No prior liver-directed therapy\n  * Cohort 3: Metastatic PD-(L)1-naive melanoma\n\n    * Uveal/ocular melanoma is excluded\n    * Must not have received prior treatment for advanced or metastatic disease except for prior adjuvant/neoadjuvant immunotherapy.\n    * For participants with a targetable BRAF mutation, prior BRAF/MEK targeted therapy is allowed if completed 4 weeks prior to first dose of study treatment.\n  * Cohorts 4 and 5: Non-squamous NSCLC\n\n    * Participants must have stage IV disease per AJCC 8th edition\n    * No known driver mutations/alterations mutation for which targeted therapy is available\n    * Must have non-squamous histology.\n    * No prior therapy for metastatic disease\n    * No prior treatment with anti-PD-(L)1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms\n* Able to provide archival tumor tissue from locations not radiated prior to biopsy. If archival tumor sample is not available a fresh baseline biopsy is required.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Measurable disease per RECIST v1.1 at baseline\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of another malignancy within 3 years of first dose of study drug\n* Active central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Previous exposure to CD40-targeted therapy\n* Currently on chronic systemic steroids in excess of physiologic replacement\n* Has had an allogeneic tissue/solid organ transplant.\n* History of autoimmune disease that has required systemic treatment in the past 2 years",
    "miscellaneous_criteria": ""
}